SCHEMBL625105

SCHEMBL625105

C=CS(=O)(=O)c1cccc(Nc2cc(S(=O)(=O)O)c(N)c3c2C(=O)c2ccccc2C3=O)c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNG2 P59768 5/20 0.78
GNB1 P62873 5/20 0.78
PHLPP2 Q6ZVD8 2/20 0.78
CYP1A2 P05177 2/20 0.78
CYP2C9 P11712 2/20 0.78
ALOX15 P16050 2/20 0.78
HSD17B10 Q99714 2/20 0.78
ALDH1A1 P00352 1/20 0.78
CYP3A4 P08684 1/20 0.78
HPGD P15428 1/20 0.78
MAPK1 P28482 1/20 0.78
CYP2C19 P33261 1/20 0.78
HIF1A Q16665 1/20 0.78
P2RY4 P51582 7/20 0.70
CHAT P28329 4/20 0.63
ENPP3 O14638 1/20 0.63
ENPP1 P22413 1/20 0.63
P2RY2 P41231 4/20 0.57
P2RY12 Q9H244 4/20 0.57
P2RY6 Q15077 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13214229 0.90 GNG2 (0.87) GNG2GNB1PHLPP2CYP1A2CYP2C9
Uniblue A SCHEMBL29533348 0.90 P2RY4 (0.71) P2RY4P2RY2P2RY12P2RY6CDK2
Uniblue A SCHEMBL19921895 0.90 P2RY4 (0.71) P2RY4P2RY2P2RY12P2RY6CDK2
SCHEMBL8656578 0.89 GNG2 (0.75) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL791497 0.89 GNG2 (0.85) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL2781947 0.88 GNG2 (1.00) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL11405626 0.87 GNG2 (0.82) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL24645555 0.87 GNG2 (0.59) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL20738852 0.86 GNG2 (0.59) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL373443 0.86 GNG2 (0.74) GNG2GNB1PHLPP2CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10302591-B2 Sharply resolving labeled protein molecular weight standards Life Technologies Corporation (US) 2019-05-28 US claimed
US-20180031522-A1 SHARPLY RESOLVING LABELED PROTEIN MOLECULAR WEIGHT STANDARDS INVITROGEN CORPORATION 2018-02-01 US claimed
EP-2976622-A2 PROTEIN STANDARD Bio-Rad Laboratories, Inc. (US) 2016-01-27 EP claimed
US-20140311909-A1 PROTEIN STANDARD BIO-RAD LABORATORIES, INC (US) 2014-10-23 US claimed
WO-2014160273-A2 PROTEIN STANDARD BIO-RAD LABORATORIES INC. (US) 2014-10-02 WO claimed
WO-2011071359-A2 COVALENT MODIFICATION OF PROTEINS FOR THE INSTANTANEOUS VISUALISATION THEREOF AND SUBSEQUENT CHARACTERISATION THROUGH MASS SPECTROMETRY Instituto Tecnológico y de Estudios Superiores de Monterrey (MX) 2011-06-16 WO claimed
EP-2069386-A2 SHARPLY RESOLVING LABELED PROTEIN MOLECULAR WEIGHT STANDARDS Life Technologies Corporation (US) 2009-06-17 EP claimed
US-20090087873-A1 SHARPLY RESOLVING LABELED PROTEIN MOLECULAR WEIGHT STANDARDS INVITROGEN CORPORATION (US) 2009-04-02 US claimed
WO-2008042495-A2 SHARPLY RESOLVING LABELED PROTEIN MOLECULAR WEIGHT STANDARDS Life Technologies Corporation (US) 2008-04-10 WO claimed
EP-1865942-A2 NOVEL INHIBITORS OF GLUTATHIONE-S-TRANSFERASE Universität Giessen (DE) 2007-12-19 EP claimed
WO-2006097472-A2 NOVEL INHIBITORS OF GLUTATHIONE-S-TRANSFERASE UNIVERSITÄT GIESSEN (DE) 2006-09-21 WO claimed
US-20050004038-A1 Bivalent inhibitors of Glutathione-S-Transferases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-01-06 US claimed
WO-2004072236-A2 METHODS AND COMPOSITIONS FOR 3-D SODIUM DODECYL SULFATE-POLYACRYLAMIDE CUBE GEL ELECTROPHORESIS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2004-08-26 WO claimed
US-5914806-A Stable electrophoretic particles for displays INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 1999-06-22 US claimed
US-5652093-A Analogues of reporter groups as background reducers in binding assays APROGENEX, INC. (US) 1997-07-29 US claimed
US-5501952-A Analogues of reporter groups as background reducers in hybridization assays APROGENEX, INC. (US) 1996-03-26 US claimed
WO-1995002699-A1 ANALOGUES OF REPORTER GROUPS AS BACKGROUNG REDUCERS IN HYBRIDIZATION ASSAYS APROGENEX, INC. (US) 1995-01-26 WO claimed
WO-2023060210-A9 MOLECULES, AND RELATED ASSAYS, TEST KITS AND METHODS SAPPHIRE BIOTECH, INC. (US) 2024-04-18 WO disclosed
US-5106951-A Antineoplastic anthracyline agents intercalated with two aromatic side chains or an oligopeptide and covalently attached to an antibody NEORX CORPORATION (US) 1992-04-21 US disclosed
EP-0329184-A2 Antimers and antimeric conjugation NEORX CORPORATION (US) 1989-08-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004038-A1 Bivalent inhibitors of Glutathione-S-Transferases GSTM1, GSTM2, GSTA2 GNG2 342/4885GNB1 470/4885PHLPP2 2936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.